Disruption of Imprinted Genes at Chromosome Region 11p15.5 in Paediatric Rhabdomyosarcoma

Neoplasia

Volumn 1, Issue 4, 1999, Pages 340-348

  Anderson, John ^a,b   Gordon, Anthony ^a   McManus, Aidan ^a   Shipley, Janet ^a   Pritchard Jones, Kathy ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

H19; Imprinting; Insulin like growth factor 2; p57KIP2; Rhabdomyosarcoma

Indexed keywords

CDKN1C PROTEIN, HUMAN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DNA BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1A PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MUSCLE PROTEIN; NUCLEAR PROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PAX3 PROTEIN, MOUSE; PAX7 PROTEIN, HUMAN; RNA H19; SOMATOMEDIN B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX7; UNTRANSLATED RNA;

ADULT; ALLELE; ARTICLE; CHILD; CHROMOSOME 11; GENETIC POLYMORPHISM; GENETICS; GENOME IMPRINTING; HETEROZYGOSITY LOSS; HUMAN; METABOLISM; MUTATION; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

ADULT; ALLELES; CHILD; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENOMIC IMPRINTING; HOMEODOMAIN PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LOSS OF HETEROZYGOSITY; MUSCLE PROTEINS; MUTATION; NUCLEAR PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, UNTRANSLATED; TRANSCRIPTION FACTORS;

EID: 0033205985     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900052     Document Type: Article

References (42)

1. Iwasa Y (1998). The conflict theory of genomic imprinting: how much can be explained? Curr Top Dev Biol 40, 255-293.
2. Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, Voute PA, and Baas F (1997). Allelotype of pediatric rhabdomyosarcoma. Oncogene 15 (11), 1309-1314.
3. Scrable H, Witte D, Shimada H, Seemayer T, Sheng WW, Soukup S, Koufos A, Houghton P, Lampkin B, and Cavenee W (1989). Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1 (1), 23-35.
4. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG (1994). Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54 (11), 2869-2872.
5. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJd, Emanuel BS, Rovera G, and Barr FG (1993). Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5 (3), 230-235.
6. Moulton T, Chung WY, Yuan L, Hensle T, Waber P, Nisen P, and Tycko B (1996). Genomic imprinting and Wilms' tumor. Med Pediatr Oncol 27 (5), 476-483.
7. Bartolomei MS, Zemel S, and Tilghman SM (1991). Parental imprinting of the mouse H19 gene. Nature 351 (6322), 153-155.
8. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y et al. (1996). An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 14 (2), 171-173.
9. Werner H, and Le Roith D (1997). The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 8 (1), 71-92.
10. Harrington EA, Bennett MR, Fanidi A, and Evan GI (1994). c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13 (14), 3286-3295.
11. Pietrzkowski Z, Sell C, Lammers R, Ullrich A, and Baserga R (1992). Roles of insulin like growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells. Mol Cell Biol 12 (9), 3883-3889.
12. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, Ullrich A, and Baserga R (1992). Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ 3 (4), 199-205.
13. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, and Baserga R (1993). Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 (23), 11217-11221.
14. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiades A, and Baserga R (1994). Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14 (6), 3604-3612.
15. van Dijk MA, van Schaik FM, Bootsma HJ, Holthuizen P, and Sussenbach JS (1991). Initial characterization of the four promoters of the human insulin-like growth factor II gene. Mol Cell Endocrinol 81 (1-3), 81-94.
16. Ekstrom TJ, Cui H, Li X, and Ohlsson R (1995). Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development 121 (2), 309-316.
17. Vu TH, and Hoffman AR (1994). Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature 371 (6499), 714-717.
18. De Moor CH, Jansen M, Bonte EJ, Thomas AA, Sussenbach JS, and Van den Brande JL (1994). Influence of the four leader sequences of the human insulin-like-growth-factor-2 mRNAs on the expression of reporter genes. Eur J Biochem 226 (3), 1039-1047.
19. Hao Y, Crenshaw T, Moulton T, Newcomb E, and Tycko B (1993). Tumour-suppressor activity of H19 RNA. Nature 365 (6448), 764-767.
20. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, and Tilghman SM (1995). Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375 (6526), 34-39.
21. Ripoche MA, Kress C, Poirier F, and Dandolo L (1997). Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. Genes Dev 11 (12), 1596-1604.
22. Lee MH, Reynisdottir I, and Massague J (1995). Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9 (6), 639-649.
23. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, and Feinberg AP (1989). Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet 44 (5), 720-723.
24. Weksberg R, and Squire JA (1996). Molecular biology of Beckwith-Wiedemann syndrome. Med Pediatr Oncol 27 (5), 462-469.
25. Weksberg R, Shen DR, Fei YL, Song QL, and Squire J (1993). Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet 5 (2), 143-150.
26. Sun FL, Dean WL, Kelsey G, Allen ND, and Reik W (1997). Transactivation of IGF2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 389 (6653), 809-815.
27. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, De Pinho RA, and Elledge SJ (1997). Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387 (6629), 151-158.
28. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K (Eds.) (1998). Current Protocols in Molecular Biology. John Wiley and Sons Inc. p. 2.2.1.
29. Tsokos M, Webber BL, Parham DM, Wesley RA, Miser A, Miser JS, Etcubanas E, Kinsella T, Grayson J, and Glatstein E (1992). Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 116 (8), 847-855.
30. Anderson J, Renshaw J, McManus A, Carter R, Mitchell C, Adams S, and Pritchard-Jones K (1997). Amplification of the t(2; 13) and t(1; 13) translocations of alveolar rhabdomyosarcoma in small formalin-fixed biopsies using a modified reverse transcriptase polymerase chain reaction. Am J Pathol 150 (2), 477-482.
31. O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboa K, and Tycko B (1997). Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum Genet 61 (2), 295-303.
32. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, and Feinberg AP (1994). Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 7 (3), 433-439.
33. Zhan S, Shapiro DN, and Helman LJ (1994). Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94 (1), 445-448.
34. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ III, and Schafer BW (1996). Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 93 (23), 13164-13169.
35. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-Jones K, and Shipley J (1996). Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 56 (14), 3220-3224.
36. Banerjee S, and Smallwood A (1995). A chromatin model of IGF2/H19 imprinting. Nat Genet 11 (3), 237-238.
37. Joyce JA, Lam WK, Catchpoole DJ, Jenks P, Reik W, Maher ER, and Schofield PN (1997). Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Hum Mol Genet 6 (9), 1543-1548.
38. Tadokoro K, Fujii H, Inoue T, and Yamada M (1991). Polymerase chain reaction (PCR) for detection of Apal polymorphism at the insulin like growth factor Il gene (IGF2). Nucleic Acids Res 19 (24), 6967.
39. Ranier S, Dobry CJ, and Feinberg AP (1994). Transcribed dinucleotide repeat polymorphism in the IGF2 gene. Hum Mol Genet 3 (2), 386.
40. Zhang Y, and Tycko B (1992). Monoallelic expression of the human H19 gene. Nat Genet 1 (1), 40-44.
41. Besnard-Guerin C, Cavenee WK, and Newsham I (1994). A new highly polymorphic DNA restriction site marker in the 5′ region of the human tyrosine hydroxylase gene (TH) detecting loss of heterozygosity in human embryonal rhabdomyosarcoma. Hum Genet 93 (3), 349-350.
42. James MR, Richard CW III, Schott JJ, Yousry C, Clark K, Bell J, Terwilliger JD, Hazan J, Dubay C, and Vignal A (1994). A radiation hybrid map of 506 STS markers spanning human chromosome 11. Nat Genet 8 (1), 70-76.